Clinical Trial

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-05
notable Primary completion moved earlier: 2026-12 -> 2026-06-10 2026-08-05
minor Completion moved earlier: 2026-12 -> 2026-06-10 2026-08-05
Trial Details
NCT Number NCT06539195
Lead Sponsor Dizal Pharmaceuticals
Conditions Diffuse Large B Cell Lymphoma
Enrollment 59 participants
Start Date 2024-03-13
Primary Completion 2026-06-10 (estimated)
Study Completion 2026-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04